JP2021529805A5 - - Google Patents
Info
- Publication number
- JP2021529805A5 JP2021529805A5 JP2021500178A JP2021500178A JP2021529805A5 JP 2021529805 A5 JP2021529805 A5 JP 2021529805A5 JP 2021500178 A JP2021500178 A JP 2021500178A JP 2021500178 A JP2021500178 A JP 2021500178A JP 2021529805 A5 JP2021529805 A5 JP 2021529805A5
- Authority
- JP
- Japan
- Prior art keywords
- ivosidenib
- powder
- ray diffraction
- diffraction pattern
- dsc
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024131926A JP2024150784A (ja) | 2018-07-06 | 2024-08-08 | イボシデニブ形態および医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694596P | 2018-07-06 | 2018-07-06 | |
| US62/694,596 | 2018-07-06 | ||
| PCT/US2019/040257 WO2020010058A1 (en) | 2018-07-06 | 2019-07-02 | Ivosidenib forms and pharmaceutical compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024131926A Division JP2024150784A (ja) | 2018-07-06 | 2024-08-08 | イボシデニブ形態および医薬組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021529805A JP2021529805A (ja) | 2021-11-04 |
| JPWO2020010058A5 JPWO2020010058A5 (https=) | 2022-07-12 |
| JP2021529805A5 true JP2021529805A5 (https=) | 2022-07-12 |
| JP7621242B2 JP7621242B2 (ja) | 2025-01-24 |
Family
ID=69059942
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500178A Active JP7621242B2 (ja) | 2018-07-06 | 2019-07-02 | イボシデニブ形態および医薬組成物 |
| JP2024131926A Withdrawn JP2024150784A (ja) | 2018-07-06 | 2024-08-08 | イボシデニブ形態および医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024131926A Withdrawn JP2024150784A (ja) | 2018-07-06 | 2024-08-08 | イボシデニブ形態および医薬組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12264148B2 (https=) |
| EP (2) | EP3817744A4 (https=) |
| JP (2) | JP7621242B2 (https=) |
| KR (2) | KR102919157B1 (https=) |
| CN (1) | CN112367995A (https=) |
| AU (2) | AU2019299352B2 (https=) |
| BR (1) | BR112021000156A2 (https=) |
| CA (1) | CA3103498A1 (https=) |
| EA (1) | EA202190217A1 (https=) |
| IL (2) | IL315423B1 (https=) |
| MA (1) | MA53099A (https=) |
| MX (2) | MX2021000068A (https=) |
| PH (1) | PH12021550017A1 (https=) |
| SG (1) | SG11202012763TA (https=) |
| TW (2) | TWI902665B (https=) |
| UA (1) | UA129800C2 (https=) |
| WO (1) | WO2020010058A1 (https=) |
| ZA (1) | ZA202008034B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT4010331T (pt) | 2019-08-08 | 2024-01-08 | Servier Lab | Um método de preparação do ivosidenib e de um seu intermediário |
| GB201912411D0 (en) * | 2019-08-29 | 2019-10-16 | Johnson Matthey Plc | Crystalline forms of ivosidenib |
| AR133410A1 (es) | 2023-08-01 | 2025-09-24 | Servier Lab | Cocristal de un inhibidor de idh1, proceso de preparación del mismo, composiciones farmacéuticas del mismo, y métodos de tratamiento que implican el mismo |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010223919B2 (en) | 2009-03-13 | 2016-03-31 | Les Laboratoires Servier | Methods and compositions for cell-proliferation-related disorders |
| EP3561077B1 (en) | 2009-10-21 | 2022-12-21 | Les Laboratoires Servier | Methods for cell-proliferation-related disorders |
| RU2013144975A (ru) * | 2011-04-08 | 2015-05-20 | Пфайзер Инк. | Кристаллические и некристаллические формы тофацитиниба и фармацевтическая композиция, содержащая тофацитиниб, и усилитель проникновения |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| UY35006A (es) * | 2012-09-06 | 2014-03-31 | Bayer Healthcare Llc | Composición farmacéutica recubierta que contiene regorafenib |
| BR122023021436A2 (pt) * | 2014-03-14 | 2023-12-12 | Les Laboratoires Servier | Formas cristalinas e composição farmacêutica de compostos terapeuticamente ativos |
| KR20240010105A (ko) * | 2014-03-14 | 2024-01-23 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
| PT3362066T (pt) | 2015-10-15 | 2021-11-16 | Celgene Corp | Terapia de combinação para tratar malignidades |
| ES2912909T3 (es) * | 2016-02-26 | 2022-05-30 | Celgene Corp | Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria |
| WO2019104318A1 (en) | 2017-11-27 | 2019-05-31 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of ivosidenib |
-
2019
- 2019-07-02 MX MX2021000068A patent/MX2021000068A/es unknown
- 2019-07-02 EP EP19829932.3A patent/EP3817744A4/en not_active Withdrawn
- 2019-07-02 WO PCT/US2019/040257 patent/WO2020010058A1/en not_active Ceased
- 2019-07-02 JP JP2021500178A patent/JP7621242B2/ja active Active
- 2019-07-02 KR KR1020217000885A patent/KR102919157B1/ko active Active
- 2019-07-02 MA MA053099A patent/MA53099A/fr unknown
- 2019-07-02 EP EP25187804.7A patent/EP4603147A3/en active Pending
- 2019-07-02 AU AU2019299352A patent/AU2019299352B2/en active Active
- 2019-07-02 KR KR1020257038241A patent/KR20250164882A/ko active Pending
- 2019-07-02 CN CN201980045552.5A patent/CN112367995A/zh active Pending
- 2019-07-02 EA EA202190217A patent/EA202190217A1/ru unknown
- 2019-07-02 BR BR112021000156-5A patent/BR112021000156A2/pt unknown
- 2019-07-02 SG SG11202012763TA patent/SG11202012763TA/en unknown
- 2019-07-02 IL IL315423A patent/IL315423B1/en unknown
- 2019-07-02 UA UAA202100436A patent/UA129800C2/uk unknown
- 2019-07-02 CA CA3103498A patent/CA3103498A1/en active Pending
- 2019-07-02 US US17/258,102 patent/US12264148B2/en active Active
- 2019-07-05 TW TW108123796A patent/TWI902665B/zh active
- 2019-07-05 TW TW114126745A patent/TWI911130B/zh active
-
2020
- 2020-12-22 ZA ZA2020/08034A patent/ZA202008034B/en unknown
- 2020-12-30 IL IL279877A patent/IL279877A/en unknown
-
2021
- 2021-01-04 PH PH12021550017A patent/PH12021550017A1/en unknown
- 2021-01-06 MX MX2023011687A patent/MX2023011687A/es unknown
-
2024
- 2024-08-08 JP JP2024131926A patent/JP2024150784A/ja not_active Withdrawn
-
2025
- 2025-05-23 AU AU2025203835A patent/AU2025203835A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI788702B (zh) | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途 | |
| JP5546717B2 (ja) | アリピプラゾール結晶質形態を調製する方法 | |
| JP6634368B2 (ja) | 複素環式化合物及びそれらの使用 | |
| JP2021529805A5 (https=) | ||
| US12365680B2 (en) | Polymorphs of the hydrochloride salt of linaprazan glurate | |
| JP2022532404A (ja) | Ｎ－［４－（クロロジフルオロメトキシ）フェニル］－６－［（３ｒ）－３－ヒドロキシピロリジン－１－イル］－５－（１ｈ－ピラゾール－５－イル）ピリジン－３－カルボキサミドの結晶性形態 | |
| WO2004000317A1 (en) | Pharmaceutical composition containing stabilised amorphous form of donepezil hydrochloride | |
| WO2016125190A2 (en) | Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof | |
| KR20260042158A (ko) | 메닌 억제제를 포함하는 약학적 조성물 | |
| JP5782438B2 (ja) | アミド化合物の結晶 | |
| JPWO2020010058A5 (https=) | ||
| US20130225830A1 (en) | Polymorphs of febuxostat | |
| TW201311240A (zh) | 非晶形哌啶基化合物之生物可利用組合物 | |
| JP2026503095A (ja) | リナプラザングルレート（ｌｉｎａｐｒａｚａｎ ｇｌｕｒａｔｅ）の臭化水素酸塩の多形 | |
| JP2013501751A (ja) | 経口用固体製剤および結晶形態のアポトーシスタンパク質インヒビター | |
| JP2024542115A (ja) | リナプラザングルレートのメシラート塩の多形体 | |
| JP5530369B2 (ja) | 新規な結晶形 | |
| JP2007269628A (ja) | 医薬化合物の結晶 | |
| JP6393310B2 (ja) | ５−クロロ−チオフェン−２−カルボン酸［（ｓ）−２−［メチル−３−（２−オキソ−ピロリジン−１−イル）−ベンゼンスルホニルアミノ］−３−（４−メチル−ピペラジン−１−イル）−３−オキソ−プロプリル］アミドの酒石酸塩 | |
| JP2019530719A (ja) | ４−（２−（（１ｒ，２ｒ）−２−ヒドロキシシクロヘキシルアミノ）ベンゾチアゾール−６−イルオキシ）−ｎ−メチルピコリンアミドの結晶形 | |
| KR101423630B1 (ko) | 비칼루타미드와 니코틴아미드의 공결정 | |
| HK40092799A (zh) | Pn6047盐酸盐的多晶型物 | |
| KR20250130654A (ko) | 리나프라잔 글루레이트의 말레산 염의 다형체 | |
| JP2023115525A (ja) | ロスバスタチンアリルエステルの結晶形態 | |
| JP2004168772A (ja) | 受容体調節剤 |